We can readily understand why investors are attracted to unprofitable companies. Indeed, CymaBay Therapeutics (NASDAQ:CBAY) stock is up 154% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.
Full Answer
Who buys CBAY stock?
CBAY stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.
Are CymaBay Therapeutics insiders selling or buying stock?
In the past three months, CymaBay Therapeutics insiders have not sold or bought any company stock. Only 4.00% of the stock of CymaBay Therapeutics is held by insiders. 74.97% of the stock of CymaBay Therapeutics is held by institutions.
How much is a share of Cymabay worth?
One share of CBAY stock can currently be purchased for approximately $3.31. How much money does CymaBay Therapeutics make? CymaBay Therapeutics has a market capitalization of $228.52 million. The biopharmaceutical company earns $-50.99 million in net income (profit) each year or ($1.15) on an earnings per share basis.
When is CymaBay Therapeutics'next quarterly earnings announcement?
CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022. View our earnings forecast for CymaBay Therapeutics. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its quarterly earnings data on Wednesday, November, 10th.
Is Cbay a good stock to invest in?
Cymabay Therapeutics Inc (NASDAQ:CBAY) The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 10.00, with a high estimate of 14.00 and a low estimate of 7.00. The median estimate represents a +395.05% increase from the last price of 2.02.
Is Cymabay Therapeutics stock a buy?
There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CymaBay Therapeutics stock.
What is the target price for CBAY?
Stock Price Target CBAYHigh$14.00Median$10.00Low$7.00Average$10.25Current Price$2.05
What does Cymabay therapeutics do?
We are a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies.
Is Cbak a buy?
Is CBAK Energy Technology Inc. stock A Buy? CBAK Energy Technology Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Is CymaBay Therapeutics a buy right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 4 buy ratings a...
Are investors shorting CymaBay Therapeutics?
CymaBay Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,000,000 shares, an increase of 33...
When is CymaBay Therapeutics' next earnings date?
CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast fo...
How were CymaBay Therapeutics' earnings last quarter?
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.3...
What price target have analysts set for CBAY?
5 equities research analysts have issued twelve-month target prices for CymaBay Therapeutics' shares. Their forecasts range from $8.00 to $14.00. O...
Who are CymaBay Therapeutics' key executives?
CymaBay Therapeutics' management team includes the following people: Mr. Sujal A. Shah , Pres, CEO & Director (Age 49, Pay $873.87k) Dr. Dennis...
Who are some of CymaBay Therapeutics' key competitors?
Some companies that are related to CymaBay Therapeutics include Erasca (ERAS) , I-Mab (IMAB) , Atea Pharmaceuticals (AVIR) , PureTech Health (P...
What other stocks do shareholders of CymaBay Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therap...
What is CymaBay Therapeutics' stock symbol?
CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."
Is Cymabay Therapeutics Inc a positive or negative stock?
The Cymabay Therapeutics Inc stock holds several negative signals and despite the positive trend, we believe Cymabay Therapeutics Inc will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
Is Cymabay Therapeutics oversold?
Cymabay Therapeutics Inc is oversold on RSI14 (18). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
LCM Capital Management Inc Buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Sells ..
Investment company LCM Capital Management Inc (Current Portfolio) buys Southern Co, Advanced Micro Devices Inc, Diageo PLC, Duke Energy Corp, Xcel Energy Inc, sells Tesla Inc, Biogen Inc, Yum China Holdings Inc, UiPath Inc, CymaBay Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, LCM Capital Management Inc..
CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade
CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CymaBay Therapeutics Inc Stock Forecast
Is CymaBay Therapeutics Inc Stock Undervalued? The current CymaBay Therapeutics Inc [ CBAY] share price is $3.23. The Score for CBAY is 66, which is 32% above its historic median score of 50, and infers lower risk than normal.
Stock Predictions
Is CymaBay Therapeutics Inc stock public? Yes, CymaBay Therapeutics Inc is a publicly traded company.
When will the Cymabay stock option vest?
The stock option will vest and become exercisable as to 25% of the underlying shares on May 17, 2022, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments from May 17, 2022, subject to Dr. Kim’s continued employment with CymaBay on such vesting dates.
Why are research and development expenses higher in 2021 than in 2020?
Research and development expenses in the three months ended March 31, 2021 were higher than the corresponding periods in 2020 primarily due to an increase in clinical trial activities following our resumption of clinical development of seladelpar in PBC in late 2020.
When did Phase 3 PBC end?
In the three months ended March 31, 2020, costs incurred were primarily associated with the termination and shutdown of our Phase 3 PBC, Phase 2b NASH, and Phase 2 PSC clinical trials, and other studies, after the seladelpar development program was placed on hold from November 2019 through July 2020.
How Long Is CymaBay Therapeutics' Cash Runway?
Looking at the last year, the company burnt through US$45m. So it had a cash runway of about 3.3 years from December 2020. There's no doubt that this is a reassuringly long runway. The image below shows how its cash balance has been changing over the last few years.
Is Cymabay Therapeutics a good stock to buy?
Of course CymaBay Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.
Is CymaBay Therapeutics' Cash Burn A Worry?
As you can probably tell by now, we're not too worried about CymaBay Therapeutics' cash burn. For example, we think its cash runway suggests that the company is on a good path. Its weak point is its cash burn relative to its market cap, but even that wasn't too bad! Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. An in-depth examination of risks revealed 2 warning signs for CymaBay Therapeutics that readers should think about before committing capital to this stock.
When will Cymabay be phase 3?
Olson expects the FDA's response to be positive, leading to the drug's progression to Phase 3 trials in early 2021, and concluding in 2023. Based on this timeline, and his estimate of the chance of the drug ultimately winning FDA approval rising to 35%, Olson rates CymaBay stock "outperform," and assigns the shares a $6 price target -- up from $4 previously.
Is Cymabay a good stock?
Flush with cash and with solid clinical results underlying its new drug, Archila sees CymaBay as a "highly favorable" stock offering much more reward than risk to investors.
Stock Price Forecast
The 9 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 12.00, with a high estimate of 14.00 and a low estimate of 9.00. The median estimate represents a +255.03% increase from the last price of 3.38.
Analyst Recommendations
The current consensus among 9 polled investment analysts is to Buy stock in Cymabay Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Buy rating. Move your mouse over past months for detail